More Evidence For Increased Risk of NAION With Ozempic or Mounjaro in Diabetes Patients NAION is Likely Associated With Other Semaglutide or Tirzepatide GLP-1RA Drugs Used for Weight Loss (Posted by Tom Lamb at Drug Injury Watch) A new medical article published August 11, 2025, online by JAMA Network Open, "Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes", provided more evidence for an increased risk of non-arteritic ischemic optic neuropathy, or NAION, with Ozempic or Mounjaro in diabetes patients. One primary issue examined by researchers in the medical study underlying this August 2025 article was whether treatment with either Ozempic (semaglutide) or Mounjaro (tirzepatide) is associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) when compared to other antidiabetic medications. From the Discussion part of this recent medical journal article: In a population of patients with type 2 diabetes who had no prior diagnosis of eye diseases, this cohort study found that semaglutide [(Ozempic)] or tirzepatide [(Mounjaro)] compared with other antidiabetic medications was associated with a differential risk of optic nerve and visual pathways, including increased risk of NAION and other optic nerve disorders, but not optic neuritis, papilledema, optic atrophy, or optic disc orders. Cumulative incidence curves began to diverge immediately after medication initiation...
https://www.drug-injury.com/dr....uginjurycom/2025/08/